Abstract
The aim of the present study was to evaluate the efficacy and β2-adrenoceptor (AR) selectivity of KUR-1246, a new uterine relaxant. Inhibition of spontaneous or drug-induced uterine contractions by KUR-1246 was evaluated in pregnant rats and rabbits by an organ bath method or by a balloon method. The selectivity of KUR-1246 was assessed simultaneously in organs isolated from late-pregnant rats. The affinity of KUR-1246 for human β1-, β2-, and β3-ARs was determined using two radioligands. KUR-1246 suppressed both spontaneous and drug-induced contractions in isolated uteri, the rank order of potency being isoproterenol > KUR-1246 > terbutaline > ritodrine. ICI-118551 (selective β2-AR antagonist) competitively antagonized the KUR-1246-induced inhibition of spontaneous uterine contractions, but CGP-20712A (selective β1-AR antagonist) and SR-58894A (selective β3-AR antagonist) did not. All β-AR agonists tested produced significant inhibition of spontaneous uterine contractions in vivo: ED30 value for KUR-1246 was 0.13 μg/kg/min, a potency about 6 times and 400 times greater than that of terbutaline and ritodrine, respectively. In contrast, the positive chronotropic effect was minimal in KUR-1246-treated rats. KUR-1246 displaced radioligand binding to β1-, β2-, and β3-ARs, the pK i values being 5.75 ± 0.03, 7.59 ± 0.08, and 4.75 ± 0.03 for β1-, β2-, and β3-ARs, respectively. For the selectivity of KUR-1246 for human β2-AR, we obtained values of 39.2 ([IC50 for β1-AR]/[IC50 for β2-AR]) and 198.2 ([IC50 for β3-AR]/[IC50 for β2-AR]), indicating an apparently higher affinity for human β2-AR than for other β-AR subtypes. The present study clearly demonstrated that KUR-1246 is a more selective β2-AR agonist than the drugs presently used for relaxing uterine muscle.
Footnotes
-
Send reprint requests to: Dr. Mamoru Kobayashi, Pharmacology Research, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Hotaka, Nagano Pref. 399-8304, Japan. E-mail:mamoru_kobayashi{at}pharm.kissei.co.jp
- Abbreviations:
- AR
- adrenoceptor
- PGF2α
- prostaglandin F2α
- Received September 6, 2000.
- Accepted January 11, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|